Cortendo AB
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Cortendo AB sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Cortendo AB: 6 sponsored US clinical trials, none currently recruiting.
Cortendo AB sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 3 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Endogenous Cushing's Syndrome, with 2 trials.
Upper-quartile sponsor footprint
Cortendo AB sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
Bioavailability of Levoketoconazole and Ketoconazole Tablets
NCT04212000
Drug Interaction Study of Levoketoconazole and Metformin
NCT03880825
Open-label Treatment in Cushing's Syndrome
NCT03621280
Levoketoconazole Food Effect Study in Healthy Subjects
NCT03768388
A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
NCT03277690
Treatment for Endogenous Cushing's Syndrome
NCT01838551
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 3 | 3 |
Therapeutic Areas
How the Cortendo AB archive is shaped
6 indexed studies, none listed as recruiting (0% open); 6 completed (100%).
Phase mix: 3 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Endogenous Cushing's Syndrome (2 trials), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Cortendo AB: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Cortendo AB sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Cortendo AB page
6 registered trials is a research-attention snapshot, not an endorsement of Cortendo AB or any single study.
- None of Cortendo AB's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Endogenous Cushing's Syndrome is the condition Cortendo AB studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Endogenous Cushing's Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cortendo AB pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.